NL
NAMS icon

Navalign LLC’s NewAmsterdam Pharma NAMS Stock Holding History

Navalign LLC’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,315
Closed -$46.1K – 351
2025
Q4 		$46.1K Buy
+1,315
New +$47.9K 0.01% 200

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Navalign LLC's NAMS Position: Q1 2026 in Review

Navalign LLC sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 1,315 shares — an estimated $46.1K sold.

Navalign LLC first reported a position in NAMS in Q4 2025 and held it in 1 quarter. The position peaked at $46.1K in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Navalign LLC reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
  • Navalign LLC sold 1,315 NewAmsterdam Pharma shares in Q1 2026, an estimated $46.1K.
  • Navalign LLC first reported a position in NewAmsterdam Pharma in Q4 2025 and held it in 1 quarter.
  • Navalign LLC's NewAmsterdam Pharma position peaked at $46.1K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.